R-miniCHOP

Phase 2Small molecule

R-miniCHOP is one of 7 small molecule programs targeting DLBCL - Diffuse Large B Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting

DLBCL - Diffuse Large B Cell LymphomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

13 competitors in DLBCL - Diffuse Large B Cell Lymphoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

1 2

Eloxatin

Teva

Phase 3

1 3

Jaypirca

Eli Lilly

Phase 2

2 4

Dexametasone

UUniversity of Malaya

Phase 3

1 5

R-CHOP

IIncyte Biosciences Japan GK

Phase 2

1 6

POLA-R-CHP

FFudan University

Phase 2

1 7

R-miniCHOP

UUniversität des Saarlandes

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Large B-Cell Lymphoma

NCT05820841

Q4 2031

Phase 2Not yet recruiting

DLBCL - Diffuse Large B Cell Lymphoma

NCT07677813

Clinical

Trials by Indication[1]

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study

Not yet recruiting·OOu Bai, MD/PHD·Phase 2·NCT07677813·66 enrolled

Large B-cell Lymphoma1 trial

A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination With Rituximab and Reduced Dose CHOP (R-miniCHOP) in OldEr Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting·UUniversität des Saarlandes·Phase 3·NCT05820841·330 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for R-miniCHOP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-miniCHOP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-miniCHOP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universität des Saarlandes company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversität des Saarlandes

R-miniCHOP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2031

Trials by Indication[1]

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News